Acasti announces dosing of first patient in gtx-104 strive-on trial

Princeton, n.j., oct. 23, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced enrollment of the first patient in the company's pivotal phase 3 strive-on safety trial (the strive-on trial–nct05995405). uthealth houston is the first site to enroll an asah patient in the strive-on trial.
ACST Ratings Summary
ACST Quant Ranking